Abstract:Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL). Recently approved treatment options for patients with relapsed/refractory (R/R) DLBCL include polatuzumab, tafasitamab, chimeric antigen receptor T-cell (CAR-T) therapy and two newly approved bispecific antibodies, epcoritamab and glofitamab. Epcoritamab (subcutaneous [SC]) is a CD3xCD20 bispecific antibody developed using the DuoBody ® platform. It was the first bispecific antibody approved for the treatment of R/R DLBCL patients after two or more lines of therapy and is the first in the class to be offered as a SC treatment, in contrast to glofitamab which is offered as an intravenous infusion. Given the different treatment options available, there is a need to understand their impact on clinical practice efficiency and institutional costs. Methods: A micro-costing analysis was developed to compare practice efficiency of treating patients with R/R DLBCL using epcoritamab versus comparator treatments (glofitamab, polatuzumab/bendamustine/rituximab [pola-BR], tafasitamab/lenalidomide [tafa-len], and axicabtagene ciloleucel [axi-cel]) over a time horizon of up to 1 year. Time for clinical personnel (pharmacy technician, pharmacist, and nurse) and chair time were estimated throughout treatment stages (pre-dosing, blood work, pre-medication, treatment administration) as well as time in hospital during post-treatment monitoring. Dosing schedules and time inputs were based on prescribing information (PI) of respective drugs, published studies, and clinical expert opinion. Institutional costs of clinical personnel and inpatient days were sourced from publicly available databases and presented in 2023 US dollars. Results: Over the 1-year time horizon, epcoritamab treatment required 35 hours of personnel time and 22 hours of chair time per patient (Table 1). With SC administration, epcoritamab is associated with improved practice efficiency with reduced personnel time (time saved per treated patient: 31 hours versus glofitamab, 0.4 hour versus pola-BR, 41 hours versus tafa-len, 22 hours versus axi-cel) and chair time (time saved per treated patient: 54 hours versus glofitamab, 22 hours versus pola-BR, 63 hours versus tafa-len, -2 hours versus axi-cel). The improved practice efficiency translates into savings in institutional personnel costs of $1,577 versus glofitamab, $2,443 versus tafa-len, and $1,295 versus axi-cel but is slightly higher ($189) when compared with pola-BR, which is a time-limited treatment of up to 6 cycles. Post-treatment monitoring varies across the treatments according to the PIs, based on recommended monitoring time and occurrence of cytokine release syndrome. While epcoritamab-treated patients were estimated to be monitored in the hospital for an average of 24.6 hours, glofitamab was projected to be associated with 37.9 hours of hospitalization for post infusion monitoring per patient. Patients receiving axi-cel therapy were estimated to be monitored in hospital for an average of 7 days according to clinical expert opinion. Due to reduced inpatient monitoring, epcoritamab results in savings in inpatient costs of $6,924 versus glofitamab and $19,234 versus axi-cel. The trends are consistent when looking at shorter time horizons including 6 months, 30 days, or using the median cycles of the treatments. Conclusion: Due to its unique SC administration, epcoritamab improves institutional practice efficiency despite more frequent dosing, saving personnel costs and inpatient costs. This could help to alleviate capacity constraints at infusion centers and ease patient scheduling. The resources saved (staff time, chair time, inpatient monitoring) can be redirected to other institutional needs, improving the availability and quality of healthcare services for patients.

The administration of immune checkpoint inhibitors via an elastomeric pump versus conventional intravenous infusion: an economic perspective

Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab

The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection

Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies

Home intravenous antibiotherapy and the proper use of elastomeric pumps: Systematic review of the literature and proposals for improved use

A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer

Interchangeability of immune checkpoint inhibitors: an urgent need for action

Opportunities for using in silico-based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors

Transitioning patients from intravenous to subcutaneous infliximab and vedolizumab for inflammatory bowel disease: what is the opportunity cost of improving access to healthcare?

Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center

Real-world assessment of attenuated dosing anti-PD1 therapy as an alternative dosing strategy in a high-income country (as defined by World Bank)

Bolusing IV Administration Sets With Monoclonal Antibodies Reduces Cost and Chair Time: A Randomized Controlled Trial

Stability of vincristine sulfate, doxorubicin hydrochloride and etoposide phosphate admixtures in polyisoprene elastomeric pump supporting transition of the EPOCH regimen to outpatient care

Health Economic Aspects of Platelet Concentrates: Comparing Cost and Reimbursement of Pathogen Inactivated and Conventional Platelet Concentrates in a German Comprehensive Cancer Center

Economic analysis of alternative pembrolizumab and nivolumab dosing strategies at an academic cancer center.

Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation

Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors

Practice Efficiency Associated with Epcoritamab for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma from an Institutional Perspective

Pump-driven clinical infusions: laboratory comparison of pump types, fluid composition and flow rates on model drug delivery applying a new quantitative tool, the pharmacokinetic coefficient of short-term variation (PK-CV)

Extended infusion of cephalosporins, penicillins and carbapenems: a cost-effective point-of-view and critical appraisal of Surviving Sepsis Campaign guidelines

Alternative Strategies for Delivering Immunotherapeutics Targeting the PD-1/PD-L1 Immune Checkpoint in Cancer